ReviewAdvances and technical standards in neurosurgery2026
Idiopathic Intracranial Hypertension: Updates on Pathophysiology and Diagnosis.
Review in Advances and technical standards in neurosurgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic intracranial hypertension (IIH) is a neurological disorder characterized by elevated intracranial pressure (ICP) without a discernible structural cause. Historically referred to as pseudotumor cerebri, IIH primarily affects young women with obesity, reflecting its close association with metabolic and hormonal imbalances. Clinical manifestations include headaches, visual disturbances, and papilledema, which, if untreated, can lead to irreversible vision loss.Pathophysiological insights reveal a complex interplay of venous hypertension, glymphatic dysfunction, cerebrospinal fluid (CSF) dynamics, and metabolic and hormonal contributions. Transverse sinus stenosis exemplifies this complexity, acting as both a cause and consequence of elevated ICP. Dysfunction in the glymphatic system, impaired CSF reabsorption, and obesity-related hormonal dysregulation further elucidate IIH's multifactorial nature. Innovations like venous sinus stenting and pharmacological interventions targeting pathways like glucagon-like peptide-1 (GLP-1) show promise in managing refractory cases.Advances in diagnostics have refined IIH identification, integrating neuro-ophthalmological assessments, lumbar puncture, and imaging modalities such as magnetic resonance imaging (MRI), magnetic resonance venography (MRV), and optical coherence tomography (OCT). These tools enhance the detection of key findings like transverse sinus stenosis, optic nerve sheath dilation, and papilledema severity. Emerging non-invasive methods offer safer, real-time monitoring potential, including ultrasound-based optic nerve sheath diameter (ONSD) measurement and machine learning-based ICP estimation.Despite the significant and recent advances, challenges in standardizing diagnostic criteria and therapeutic approaches persist. This review integrates recent research to highlight critical developments, underscoring unresolved questions on pathophysiology and advocating for a multidisciplinary approach for the diagnosis. Future directions include hybrid diagnostic strategies and leveraging artificial intelligence to refine non-invasive monitoring and therapeutic precision.
Indexed as
Identifiers
42393442What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.